Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating the efficacy and safety of pegozafermin in patients with compensated cirrhosis due to metabolic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Nonalcoholic Steatohepatitis with Compensated Cirrhosis

Drugs mentioned

• Pegozafermin (pegozafermin)

Snippet

Sponsor: 89bio, Inc. | Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | Phase 3 | Status: RECRUITING